Background Human epidermal growth factor receptor 2 (HER2)–targeted therapies have
not been approved for patients with non–small-cell lung cancer (NSCLC). The efficacy and …

Background The standard of care for operable, stage I, non-small-cell lung cancer (NSCLC)
is lobectomy with mediastinal lymph node dissection or sampling. Stereotactic ablative …

Background Up to 50% of curative surgery for suspected non-small-cell lung cancer is
unsuccessful. Accuracy of positron emission tomography (PET) with 18-fluorodeoxyglucose ( 18 …

Background BRAF V600E mutation occurs in 1–2% of lung adenocarcinomas and acts as
an oncogenic driver. Dabrafenib, alone or combined with trametinib, has shown substantial …

Tumor-educated blood platelets (TEPs) are implicated as central players in the systemic
and local responses to tumor growth, thereby altering their RNA profile. We determined the …

Cancer immunotherapies have shown substantial clinical activity for a subset of patients
with epithelial cancers. Still, technological platforms to study cancer T-cell interactions for …

Background Induction chemotherapy before surgical resection increases survival compared
with surgical resection alone in patients with stage IIIA-N2 non–small-cell lung cancer (…

Organoids are self‐organizing 3D structures grown from stem cells that recapitulate essential
aspects of organ structure and function. Here, we describe a method to establish long‐term…

Metastatic cancer is a major cause of death and is associated with poor treatment efficacy. A
better understanding of the characteristics of late-stage cancer is required to help adapt …

Background Among patients with non–small-cell lung cancer (NSCLC), MET exon 14
skipping mutations occur in 3 to 4% and MET amplifications occur in 1 to 6%. Capmatinib, a …